Literature DB >> 33494879

Transfusion and Cellular Therapy in Pediatric Sickle Cell Disease.

Yan Zheng1, Stella T Chou2.   

Abstract

Red blood cell (RBC) transfusion is critical in managing acute and chronic complications of sickle cell disease. Alloimmunization and iron overload remain significant complications of transfusion therapy and are minimized with prophylactic Rh and K antigen RBC matching and iron chelation. Matched sibling donor hematopoietic stem cell transplant (HSCT) is a curative therapeutic option. Autologous hematopoietic stem cell (HSC)-based gene therapy has recently shown great promise, for which obtaining sufficient HSCs is essential for success. This article discusses RBC transfusion indications and complications, transfusion support during HSCT, and HSC mobilization and collection for autologous HSCT with gene therapy.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alloimmunization; Apheresis; Hematopoietic stem cell transplant; Iron overload; Plerixafor; Red blood cell transfusion; Sickle cell disease

Mesh:

Substances:

Year:  2020        PMID: 33494879      PMCID: PMC7842358          DOI: 10.1016/j.cll.2020.10.007

Source DB:  PubMed          Journal:  Clin Lab Med        ISSN: 0272-2712            Impact factor:   1.935


  98 in total

1.  Exchange versus simple transfusion for acute chest syndrome in sickle cell anemia adults.

Authors:  Jeff M Turner; Jason B Kaplan; Hillel W Cohen; Henny H Billett
Journal:  Transfusion       Date:  2009-05-01       Impact factor: 3.157

2.  Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia.

Authors:  Michael R DeBaun; Mae Gordon; Robert C McKinstry; Michael J Noetzel; Desiree A White; Sharada A Sarnaik; Emily R Meier; Thomas H Howard; Suvankar Majumdar; Baba P D Inusa; Paul T Telfer; Melanie Kirby-Allen; Timothy L McCavit; Annie Kamdem; Gladstone Airewele; Gerald M Woods; Brian Berman; Julie A Panepinto; Beng R Fuh; Janet L Kwiatkowski; Allison A King; Jason M Fixler; Melissa M Rhodes; Alexis A Thompson; Mark E Heiny; Rupa C Redding-Lallinger; Fenella J Kirkham; Natalia Dixon; Corina E Gonzalez; Karen A Kalinyak; Charles T Quinn; John J Strouse; J Philip Miller; Harold Lehmann; Michael A Kraut; William S Ball; Deborah Hirtz; James F Casella
Journal:  N Engl J Med       Date:  2014-08-21       Impact factor: 91.245

Review 3.  Complex Transfusion Issues in Pediatric Hematopoietic Stem Cell Transplantation.

Authors:  Jennifer Webb; Allistair Abraham
Journal:  Transfus Med Rev       Date:  2016-06-18

Review 4.  Hematopoietic Stem and Progenitor Cells (HSPCs).

Authors:  Kamila Bujko; Magda Kucia; Janina Ratajczak; Mariusz Z Ratajczak
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

5.  Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group.

Authors:  E P Vichinsky; L D Neumayr; A N Earles; R Williams; E T Lennette; D Dean; B Nickerson; E Orringer; V McKie; R Bellevue; C Daeschner; E A Manci
Journal:  N Engl J Med       Date:  2000-06-22       Impact factor: 91.245

6.  Silent cerebral infarcts occur despite regular blood transfusion therapy after first strokes in children with sickle cell disease.

Authors:  Monica L Hulbert; Robert C McKinstry; JoAnne L Lacey; Christopher J Moran; Julie A Panepinto; Alexis A Thompson; Sharada A Sarnaik; Gerald M Woods; James F Casella; Baba Inusa; Jo Howard; Fenella J Kirkham; Kofi A Anie; Jonathan E Mullin; Rebecca Ichord; Michael Noetzel; Yan Yan; Mark Rodeghier; Michael R Debaun
Journal:  Blood       Date:  2010-10-12       Impact factor: 22.113

7.  Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major.

Authors:  G M Brittenham; A R Cohen; C E McLaren; M B Martin; P M Griffith; A W Nienhuis; N S Young; C J Allen; D E Farrell; J W Harris
Journal:  Am J Hematol       Date:  1993-01       Impact factor: 10.047

Review 8.  Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.

Authors:  Barbara P Yawn; George R Buchanan; Araba N Afenyi-Annan; Samir K Ballas; Kathryn L Hassell; Andra H James; Lanetta Jordan; Sophie M Lanzkron; Richard Lottenberg; William J Savage; Paula J Tanabe; Russell E Ware; M Hassan Murad; Jonathan C Goldsmith; Eduardo Ortiz; Robinson Fulwood; Ann Horton; Joylene John-Sowah
Journal:  JAMA       Date:  2014-09-10       Impact factor: 56.272

9.  Safety and efficacy of plerixafor dose escalation for the mobilization of CD34+ hematopoietic progenitor cells in patients with sickle cell disease: interim results.

Authors:  Farid Boulad; Tsiporah Shore; Koen van Besien; Caterina Minniti; Mihaela Barbu-Stevanovic; Sylvie Wiener Fedus; Fabiana Perna; June Greenberg; Danielle Guarneri; Vijay Nandi; Audrey Mauguen; Karina Yazdanbakhsh; Michel Sadelain; Patricia A Shi
Journal:  Haematologica       Date:  2018-02-01       Impact factor: 9.941

10.  Safe and efficient peripheral blood stem cell collection in patients with sickle cell disease using plerixafor.

Authors:  Naoya Uchida; Alexis Leonard; David Stroncek; Sandhya R Panch; Kamille West; Eoghan Molloy; Thomas E Hughes; Sara Hauffe; Tiffani Taylor; Courtney Fitzhugh; Jane S Hankins; Megan Wilson; Akshay Sharma; Shengdar Q Tsai; Mitch J Weiss; Matthew Hsieh; John F Tisdale
Journal:  Haematologica       Date:  2020-10-01       Impact factor: 9.941

View more
  1 in total

Review 1.  Indications for transfusion in the management of sickle cell disease.

Authors:  Hyojeong Han; Lisa Hensch; Venée N Tubman
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.